MaxCyte publishes corporate presentation on scalable electroporation platform for cell and gene therapies
Reuters2026/08/12 20:21- MaxCyte outlined its cell-engineering platform strategy focused on non-viral electroporation for ex vivo cell and gene therapy manufacturing.
- 2025 revenue of USD 33 million; non-GAAP adjusted gross margin of 81%.
- Cash and cash equivalents of USD 142 million as of June 30, 2026.
- Strategic platform license portfolio: 29 SPL customers; 13 clinical and commercial therapies supported; CASGEVY listed as a commercial program.
- Clinical SPL pipeline: 12 active clinical programs; about USD 110 million in precommercial milestone potential; more than USD 30 million milestones received to date.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Stifel raises Adobe's target price to $225
Marubeni releases transcript of IR Day 2026 event
Ant International partners with Visa (V.US) and Mastercard (MA.US) to jointly launch AI agent payment trust system
Fintech company Ant International announced on Thursday that it has reached a partnership with Visa and Mastercard to jointly establish new standards for AI agent payments, betting that consumers and businesses will increasingly use AI agents to complete transactions.
Aramis Group releases transcript of Q3 FY2026 revenue presentation
Crypto prices
More
